MedTrace Logo

Intravitreal Pegaptanib in Treatment of Choroidal Neovascularisation Secondary to Pathologic Myopia

NCT01218230 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL

Last updated 2015-09-02

No results posted yet for this study

Summary

Intravitreal pegaptanib for treatment of choroidal neovascularisation secondary to pathologic myopia

Conditions

  • Myopic Choroidal Neovascular Membrane

Interventions

DRUG

Intravitreal Pegaptanib

Intravitreal pegaptanib, 0.3 mg, every 6 weeks for 3 injections and then PRN.

Sponsors & Collaborators

  • Pfizer

    collaborator INDUSTRY

  • L.V. Prasad Eye Institute

    lead OTHER

Principal Investigators

  • Raja Narayanan, MD · LV Prasad Eye Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-12-31
Primary Completion
2012-07-31
Completion
2012-07-31

Countries

  • India

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01218230 on ClinicalTrials.gov